- Date2025-07-30
Publication of Review Result of the 6th Pharmaceutical Reimbursement Evaluation Committee of 2025
□ The Health Insurance Review and Assessment Service (President Kang Jung-Gu) releases the results of the deliberations of the 6th Pharmaceutical Reimbursement Evaluation Committee in 2025 as follows.
○ Deliberation Results on the Appropriateness of Expanding the Scope of Use for Risk-Sharing Agreement Pharmaceutical
|
Product |
Pharmaceutical company |
Efficacy and effectiveness |
Deliberation results |
|
Jemperli Inj. (Dostarlimab) |
GlaxoSmithKline Co., Ltd. |
Newly diagosed dMMR/MSI-H advanced or recurrent endometrial cancer |
The expansion of the reimbursement scope is deemed appropriate |
|
Enspryngg Prefilled Syringe Inj. (Satralizumab) |
Roche Korea Ltd. |
Aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-lgG+ NMOSD) |
The expansion of the reimbursement scope is deemed appropriate |
※ Pursuant to Article 11(2) of the Rules on the Criteria for National Health Insurance Reimbursement, the President of the Health Insurance Review and Assessment Service evaluates the adequacy of reimbursement for drugs after deliberation by the Pharmaceutical Reimbursement Evaluation Committee. The final evaluation results may be subject to change if there are changes in the detailed reimbursement scope and items of the drug, changes in the approval of the item applied for decision, or revocation (cancellation) of the approval.
